非小细胞肺癌EGFR-TKIs获得性耐药机制研究进展

Research advances in mechanism of acquired resistance to EGFR-TKIs in non-small cell lung cancer

摘要: 非小细胞肺癌(non-small cell lung cancer，NSCLC)是肺癌的主要病理类型，约占肺癌的85%，严重威胁人类健康。表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors，EGFR-TKIs)的快速研发与应用使成千上万的NSCLC患者受益。然而大部分患者不可避免地会对EGFR-TKIs产生获得性耐药，最终导致疾病进展、复发和死亡。本综述重点关注NSCLC患者EGFR-TKIs靶向治疗获得性耐药分子机制的研究进展，以期为EGFR-TKIs耐药相关基础研究和临床治疗研究提供参考。

Abstract: As the main pathological type of lung cancer, non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer, and threatens human health seriously. The rapid development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has benefited thousands of the patients with NSCLC. Unfortunately, acquired resistance to EGFR TKIs is inevitable, eventually resulting in disease progression, recurrence and death. This review focuses on the latest research advances in the mechanism of acquired resistance to EGFR-TKIs in patients with NSCLC.